EPAX to Unveil Metabolic Syndrome Study Results
The team will demonstrate that marine Omega-3 fatty acids, in particular DHA (EPAX 1050 TG) can recapture the genetic control of this metabolic disorder caused by being overweight and a sedentary lifestyle.
21 May 2010 --- Leading Omega-3 supplier, EPAX AS, will present results from studies related to the treatment and prevention of metabolic syndrome and Type 2 Diabetes at the ISSFAL conference which runs from 29th May – 2nd June in Maastricht, Netherlands.
Dr Kopecky and collaborators from The Academy of Science of the Czech Republic, who work closely with EPAX AS, will present the data at a presentation from 10.30-12 noon on Monday 31st May.
The team will demonstrate that marine Omega-3 fatty acids, in particular DHA (EPAX 1050 TG) can recapture the genetic control of this metabolic disorder caused by being overweight and a sedentary lifestyle. The results show that DHA is effective in restoring efficient fat burning thereby regaining insulin sensitivity which is reduced in this subset of patients.
EPAX is a leading sponsor of the 9th ISSFAL conference whose overall theme is “Lipids in Metabolic Health & Disease”. Gunilla Traberg, marketing manager, EPAX AS comments, “We are delighted to be a silver sponsor of this year’s ISSFAL conference. ISSFAL provides us with a great platform to present the findings of this ground breaking study. We are proud that our advanced technological processing systems have enabled us to develop formulas like EPAX 1050 TG which have the potential to improve the health and wellbeing of a great number of people.”
EPAX, who produce the most clinically researched marine Omega-3 ingredients in the world, has placed significant investment in clinical trials for the last thirty years, documenting the efficacy and safety of its Omega-3 concentrates.
Dr Morten Bryhn, MD, Scientific Adviser adds, “The findings of this study show the potential for DHA to have a real impact on the treatment of metabolic syndrome.
“This condition affects a vast number of people and prevalence is increased with age. We are hopeful that the findings will steer a new line of treatment for people suffering or at risk from this potentially serious condition.”
EPAX Omega-3 formulas have been used in more than 100 clinical studies which have been published in peer reviewed scientific journals. EPAX prides itself on its testing and validation processes and places purity, quality and innovation at the heart of all business operations.
